Original Publication Date: 1 September, 2014
Publication / Source: Clinical Investigation
Authors: Sarah A Holstein, Philip L McCarthy
Multiple myeloma is characterized by monoclonal protein production, immune dysregulation, renal dysfunction and lytic bone disease. The backbone of therapy for patients eligible for high-dose therapy has been induction therapy followed by consolidation with autologous stem cell transplant. The introduction of immunomodulatory drugs and proteasome inhibitors has led to a dramatic improvement in responses to induction therapy, translating to improved survival following transplant.